We used a specific AP-1 inhibitor T5224, which has advanced to phase II clinical trial but not been previously tested for the treatment of malignant gliomas.44 10-day treatment at T2 dramatically reduced the area and density of TNP cells, and restricted their invasion (4/4) (Fig. 7d). This evidence concerns the gene JUNB and malignant glioma.